27698061|t|Mnk1 (Mitogen-Activated Protein Kinase-Interacting Kinase 1) Deficiency Aggravates Cardiac Remodeling in Mice
27698061|a|Identifying the key factor involved in cardiac remodeling is critically important for developing novel strategies to protect against heart failure. Here, the role of Mnk1 (mitogen-activated protein kinase-interacting kinase 1) in cardiac remodeling was clarified. Cardiac remodeling was induced by transverse aortic constriction in Mnk1 - knockout mice and their wild-type control mice. After 4 weeks of transverse aortic constriction, Mnk1 - knockout mice developed exaggerated cardiac hypertrophy, fibrosis, dysfunction, and cardiomyocyte apoptosis and showed increased ERK1/2 (extracellular signal-regulated kinase 1/2) activation along with reduced sprouty2 expression. In line with the in vivo studies, Mnk1 knockdown by Mnk1 siRNA transfection induced exaggerated angiotensin II - induced cardiomyocyte hypertrophy in neonatal rat ventricular myocytes (NRVMs). Moreover, adenovirus -mediated overexpression of Mnk1 in NRVMs protected cardiomyocytes from angiotensin II - induced hypertrophy. In addition, overexpression of sprouty2 rescued NRVMs with Mnk1 knockdown from angiotensin II - induced hypertrophy. In accordance with the in vivo studies, as compared with the control group, Mnk1 knockdown led to hyperphosphorylation of ERK1 / 2 and suppression of the sprouty2 expression in angiotensin II - treated NRVMs; furthermore, Mnk1 overexpression led to hypophosphorylation of ERK1 / 2 in angiotensin II - treated NRVMs. In addition, sprouty2 overexpression suppressed the activation of ERK1 / 2 in angiotensin II - treated NRVMs with Mnk1 knockdown. Impressively, MnK1 - knockout mice with overexpression of sprouty2 exhibited signs of a blunted cardiac hypertrophic response. Mnk1 likely carries out a suppressive function in cardiac hypertrophy via regulating the sprouty2 / ERK1/2 pathway. It implicates Mnk1 in the development of cardiac remodeling.
27698061	0	4	Mnk1	T116,T126	C1449082
27698061	6	59	Mitogen-Activated Protein Kinase-Interacting Kinase 1	T116,T126	C1449082
27698061	61	71	Deficiency	T169	C0011155
27698061	72	82	Aggravates	T033	C0436331
27698061	83	101	Cardiac Remodeling	T046	C3658220
27698061	105	109	Mice	T015	C0025929
27698061	110	121	Identifying	T080	C0205396
27698061	130	136	factor	T169	C1521761
27698061	149	167	cardiac remodeling	T046	C3658220
27698061	213	223	strategies	T170	C0679716
27698061	227	234	protect	T033	C1545588
27698061	243	256	heart failure	T047	C0018801
27698061	268	272	role	T170	C1704326
27698061	276	280	Mnk1	T116,T126	C1449082
27698061	282	335	mitogen-activated protein kinase-interacting kinase 1	T116,T126	C1449082
27698061	340	358	cardiac remodeling	T046	C3658220
27698061	374	392	Cardiac remodeling	T046	C3658220
27698061	397	404	induced	T169	C0205263
27698061	408	418	transverse	T082	C0205106
27698061	419	438	aortic constriction	T046	C0597891
27698061	442	446	Mnk1	T028	C1334509
27698061	449	462	knockout mice	T015	C0206745
27698061	473	495	wild-type control mice	T015	C1520150
27698061	505	510	weeks	T079	C0439230
27698061	514	524	transverse	T082	C0205106
27698061	525	544	aortic constriction	T046	C0597891
27698061	546	550	Mnk1	T116,T126	C1449082
27698061	553	566	knockout mice	T015	C0206745
27698061	577	588	exaggerated	T080	C0442801
27698061	589	608	cardiac hypertrophy	T046	C1383860
27698061	610	618	fibrosis	T046	C0016059
27698061	620	631	dysfunction	T046	C0277785
27698061	637	650	cardiomyocyte	T025	C0225828
27698061	651	660	apoptosis	T043	C0162638
27698061	672	681	increased	T081	C0205217
27698061	682	743	ERK1/2 (extracellular signal-regulated kinase 1/2) activation	T044	C1148560
27698061	755	762	reduced	T080	C0392756
27698061	763	771	sprouty2	T116,T123	C0765743
27698061	772	782	expression	T045	C1171362
27698061	801	816	in vivo studies	T062	C0681829
27698061	818	822	Mnk1	T028	C1334509
27698061	823	832	knockdown	T063	C2350567
27698061	836	840	Mnk1	T028	C1334509
27698061	841	846	siRNA	T114,T123	C1099354
27698061	847	859	transfection	T063	C0040669
27698061	860	867	induced	T169	C0205263
27698061	868	879	exaggerated	T080	C0442801
27698061	880	894	angiotensin II	T116,T121,T123	C0003009
27698061	897	904	induced	T169	C0205263
27698061	905	930	cardiomyocyte hypertrophy	T033	C4227331
27698061	934	942	neonatal	T100	C0021289
27698061	943	946	rat	T015	C0034693
27698061	947	967	ventricular myocytes	T025	C2339371
27698061	969	974	NRVMs	T025	C2339371
27698061	987	997	adenovirus	T005	C0001483
27698061	987	1022	adenovirus -mediated overexpression	T045	C1514559
27698061	1026	1030	Mnk1	T116,T126	C1449082
27698061	1034	1039	NRVMs	T025	C2339371
27698061	1050	1064	cardiomyocytes	T025	C0225828
27698061	1070	1084	angiotensin II	T116,T121,T123	C0003009
27698061	1087	1094	induced	T169	C0205263
27698061	1095	1106	hypertrophy	T033	C4227331
27698061	1121	1135	overexpression	T045	C1514559
27698061	1139	1147	sprouty2	T116,T123	C0765743
27698061	1148	1155	rescued	T169	C0205245
27698061	1156	1161	NRVMs	T025	C2339371
27698061	1167	1171	Mnk1	T028	C1334509
27698061	1172	1181	knockdown	T063	C2350567
27698061	1187	1201	angiotensin II	T116,T121,T123	C0003009
27698061	1204	1211	induced	T169	C0205263
27698061	1212	1223	hypertrophy	T033	C4227331
27698061	1248	1263	in vivo studies	T062	C0681829
27698061	1286	1299	control group	T096	C0009932
27698061	1301	1305	Mnk1	T028	C1334509
27698061	1306	1315	knockdown	T063	C2350567
27698061	1323	1343	hyperphosphorylation	T044	C1148560
27698061	1347	1351	ERK1	T116,T126	C0082529
27698061	1354	1355	2	T116,T126	C0170168
27698061	1360	1371	suppression	T169	C1260953
27698061	1379	1387	sprouty2	T116,T123	C0765743
27698061	1388	1398	expression	T045	C1171362
27698061	1402	1416	angiotensin II	T116,T121,T123	C0003009
27698061	1419	1426	treated	T169	C1522326
27698061	1427	1432	NRVMs	T025	C2339371
27698061	1447	1451	Mnk1	T116,T126	C1449082
27698061	1452	1466	overexpression	T045	C1514559
27698061	1474	1493	hypophosphorylation	T044	C1148560
27698061	1497	1501	ERK1	T116,T126	C0082529
27698061	1504	1505	2	T116,T126	C0170168
27698061	1509	1523	angiotensin II	T116,T121,T123	C0003009
27698061	1526	1533	treated	T169	C1522326
27698061	1534	1539	NRVMs	T025	C2339371
27698061	1554	1562	sprouty2	T116,T123	C0765743
27698061	1563	1577	overexpression	T045	C1514559
27698061	1578	1588	suppressed	T169	C1260953
27698061	1593	1603	activation	T045	C0599177
27698061	1607	1611	ERK1	T116,T126	C0082529
27698061	1614	1615	2	T116,T126	C0170168
27698061	1619	1633	angiotensin II	T116,T121,T123	C0003009
27698061	1636	1643	treated	T169	C1522326
27698061	1644	1649	NRVMs	T025	C2339371
27698061	1655	1659	Mnk1	T028	C1334509
27698061	1660	1669	knockdown	T063	C2350567
27698061	1685	1689	MnK1	T116,T126	C1449082
27698061	1692	1705	knockout mice	T015	C0206745
27698061	1711	1725	overexpression	T045	C1514559
27698061	1729	1737	sprouty2	T116,T123	C0765743
27698061	1748	1753	signs	T169	C0220912
27698061	1759	1766	blunted	T080	C1997138
27698061	1767	1787	cardiac hypertrophic	T046	C1383860
27698061	1788	1796	response	T033	C1704632
27698061	1798	1802	Mnk1	T116,T126	C1449082
27698061	1824	1835	suppressive	T169	C0205367
27698061	1836	1844	function	T169	C0542341
27698061	1848	1867	cardiac hypertrophy	T046	C1383860
27698061	1872	1882	regulating	T038	C1327622
27698061	1887	1895	sprouty2	T116,T123	C0765743
27698061	1898	1912	ERK1/2 pathway	T044	C3179231
27698061	1928	1932	Mnk1	T116,T126	C1449082
27698061	1940	1951	development	T169	C1527148
27698061	1955	1973	cardiac remodeling	T046	C3658220